AI Is Halving Regulatory Workflows: The Akkodis-Biolevate Partnership
Akkodis and Biolevate partnered to deploy governed AI across regulated industries, claiming clinical report times cut in half with traceable, auditable workflows.
The partnership
Akkodis, the global tech services company and Adecco Group subsidiary with 40,000 engineers across more than 30 countries, has formally partnered with Biolevate to deploy AI across heavily regulated industries. The alliance was announced September 28-29, 2026, with an initial rollout in France and Belgium before expanding globally.
The centerpiece is Biolevate's AI platform ELISE, which combines natural language processing, computer vision, and graph-based AI to manage knowledge workflows. The key difference from a general chatbot: ELISE is built for controlled sources and traceable evidence, with expert oversight baked in. Akkodis contributes consulting, engineering, and regulatory expertise to integrate the platform into client operations.
The claimed results
The headline numbers, from Biolevate's internal performance data:
- Scientific literature reviews completed up to 2.5 times faster - Clinical study report generation and regulatory dossier preparation time reduced by up to 50% - MedTech development workflows accelerated by up to 30%
The target sectors are life sciences, aerospace, defense, and energy -- industries where documentation is not paperwork but the product. High-value workflows include scientific writing, regulatory submissions, validation engineering, and medical device development lifecycle management.
"Combining advanced AI with deep human expertise" is how Akkodis President and CEO Jo Debecker described the partnership. Biolevate co-founder and CEO Joel Belafa said it lets teams "redefine how they work in the AI era, boosting productivity and safeguarding critical knowledge." Biolevate, backed by EQT Ventures and Orange Ventures, already serves pharmaceutical clients including Sanofi and Merck/MSD.
What this means for your business
Regulated industries are where AI's ROI is clearest. Compliance and documentation work is expensive, repetitive, and auditable -- the exact combination where governed AI beats both humans alone and generic chatbots.
Action steps:
1. Don't deploy a general chatbot for regulated work. The winning pattern here is governed AI: controlled sources, traceable evidence, human sign-off. A generic LLM drafting your compliance documents is a liability, not a shortcut. 2. Start with your most expensive documentation. Regulatory dossiers, clinical reports, validation packages -- wherever senior experts spend hours on formatting and cross-referencing, that's your highest-ROI pilot. 3. Demand audit trails from AI vendors. If a vendor cannot show you the source behind every generated paragraph, walk away. Traceability is the price of admission in regulated work. 4. Pair AI with domain experts, not replacements. Akkodis' model is 40,000 engineers plus AI -- the productivity comes from experts moving faster, not from removing them. Plan your staffing the same way.